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The aim of this phase II study was to assess the feasibility and efficacy of a specific three-dimensional conformal radiotherapy
technique with concurrent continuous infusion of 5-fluorouracil (CI 5FU) sandwiched between gemcitabine chemotherapy in patients
with locally advanced pancreatic cancer. Patients with inoperable cancer in the pancreatic head or body without metastases were
given gemcitabine at 1000mgm
 2 weekly for 3 weeks followed by a 1-week rest and a 6-week period of radiotherapy and
concurrent CI 5FU (200mgm
 2day
 1). The defined target volume was treated to 54Gy in 30 daily fractions of 1.8Gy. After 4
weeks’ rest, gemcitabine treatment was re-initiated for three cycles (days 1, 8, 15, q28). Forty-one patients were enrolled. At the end
of radiotherapy, one patient (2.4%) had a complete response and four patients (9.6%) had a partial response; at the end of treatment,
three patients (7.3%) had a complete response and two patients (4.9%) had a partial response. Median survival time was 11.7 months,
median time to progression was 7.1 months, and median time to failure of local control was 11.9 months. The 1- and 2-year survival
rates were 46.3 and 9.8%, respectively. Treatment-related grade 3 and 4 toxicities were reported by 16 (39.0%) and four (9.8%)
patients, respectively. Sixteen out of 41 patients did not complete the planned treatment and nine due to disease progression. This
approach to treatment of locally advanced pancreatic cancer is safe and promising, with good local control for a substantial
proportion of patients, and merits testing in a randomised trial.
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Pancreatic cancer is characterised by a tendency for both metastatic
spread and local failure; it is one of the most difficult cancers to treat
and has a 5-year survival rate of 4% (Jemal et al, 2005). Surgical
resection gives the best chance for a possible cure; however, only
10–20% of patients present with potentially resectable pancreatic
cancer, and most of these patients will ultimately succumb to
recurrent or metastatic disease. The majority of patients with
pancreatic cancer present with locally advanced or metastatic
disease that is inoperable (Cardenes et al,2 0 0 6 ) .
Chemotherapy as a sole modality improves survival in
patients with locally advanced or metastatic disease (Palmer
et al, 1994; Glimelius et al, 1996); however, even with the current
regimens, median overall survival has ranged from 3.3 to 11.5
months in phase II trials and has generally been not more than 7
months in phase III trials (Burris et al, 1997; Berlin et al, 2002;
Colucci et al, 2002; Maisey et al, 2002; Moore et al, 2003; Petty et al,
2003; Rocha Lima et al, 2004; Lopes and Rocha Lima, 2005; Louvet
et al, 2005; Oettle et al, 2005). There is little published information
on the effectiveness of chemotherapy alone in preventing local
failure, but an apparent improvement in survival has been
reported in two recent large phase III studies, which had a
significant subset of patients with locally advanced disease
(Cunningham et al, 2005; Poplin et al, 2006a). The median survival
times in the locally advanced groups were 9.9 months (J
Neoptolemos, personal communication) and 9.1 months (Poplin
et al, 2006b).
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have been in response to combined chemotherapy and radio-
therapy with survival times ranging from 8 to 11 months in studies
conducted in the 1980s, and from 8 to 14.5 months in more recent
studies (Dickler and Abrams, 2005; Wilkowski et al, 2005). The
delivery of adequate doses of radiation to the pancreas is limited
by the sensitivity of the normal structures nearby including the
kidneys, liver, stomach, small intestine, and spinal cord. Specific
three-dimensional conformal radiotherapy (3D CRT) techniques
employ computed tomography (CT) planning to design radiation
beams that conform much more closely to the shape of the tumour
than is possible with the older two-dimensional techniques,
allowing a higher dose to be delivered to the tumour while
confining the dose to the surrounding healthy tissue to within safe
and tolerable levels (Emami et al, 1991).
There is no common approach to the management of locally
advanced pancreatic cancer in Australia and New Zealand.
Multimodal treatment approaches are the most likely avenues for
further development. The aim of this open-label phase II study was
to determine the toxicity and efficacy of protocol-specific 3D CRT
integrated with modern chemotherapy in the treatment of
locoregional pancreatic cancer, including toxicity attributable to
late effects of radiotherapy. Two independent cohorts of patients in
Australia were studied; we report here on the locally advanced
cohort, where surgical resection was not possible and the aim of
the treatment was to obtain prolonged local control. Further
analysis of the entire study population (including quality of life)
will be reported elsewhere.
MATERIALS AND METHODS
Eligibility criteria
Eligible patients for this prospective phase II study (B9E-AY-S168)
had a histological or cytological diagnosis of pancreatic adeno-
carcinoma in the head or body of the pancreas, with metastatic
disease excluded on whole body CT series, and locoregional
staging of the primary disease undertaken with dual-phase spiral
CT. Other inclusion criteria included ECOG performance status
of 0–2; adequate bone marrow function (white blood cell count
X3.5 10
9l
 1, absolute neutrophil count (ANC) X1.5 10
9l
 1,
platelets X100 10
9l
 1, and haemoglobin X10.0gdl
 1); and
serum creatinine p150mmoll
 1. Exclusion criteria included prior
cytotoxic chemotherapy; significant loss of body weight (e.g.,
415% weight loss since surgery or diagnosis); and previous
abdominal radiotherapy. The study was approved by the human
Ethics Review Boards of the participating institutions and
conducted according to ICH Good Clinical Practice Guidelines,
including obtaining written informed consent. Two studies were
undertaken in parallel, investigating this treatment programme as
both definitive therapy for locally advanced inoperable patients
and adjuvant therapy in the management of high-risk resected
patients. To be eligible for the locally advanced arm, all patients
must have been assessed by a surgeon specialising in the upper
gastrointestinal tract and considered inoperable or strongly
declined surgery. At the time of initiating this study, it was not
the policy nor belief of surgeons in Australia that downstaging was
a feasible strategy, and it is the practice of most surgeons to
undertake exploration of patients considered to be borderline
operable. No patients who were offered surgery, who then refused,
were reported by the investigators as a reason for recruitment for
this trial.
Study design
One cycle of gemcitabine chemotherapy was planned, followed by
radiotherapy and concomitant CI 5FU, 4 weeks of rest, and an
additional three cycles of gemcitabine chemotherapy (Figure 1).
Each cycle consisted of gemcitabine (1000mgm
 2) administered
weekly for 3 weeks followed by a week of rest. Gemcitabine was
given by intravenous infusion approximately for 30min. Patients
were followed up every 3 months for 2 years. A full blood count
was performed on days 1, 8, and 15 of the chemotherapy cycles and
weekly during radiotherapy.
Follow-up after completion of the treatment was every 2 months.
This included physical examination, full blood count, liver
function, and CA 19-9 levels. CT scans were done on the basis of
either clinical suspicion on the part of the investigator or three
successive rises in CA 19-9 levels.
Gemcitabine treatment
To start the cycle, the ANC had to be X1.5 10
9l
 1 and platelets
X100 10
9l
 1. Dose adjustments for haematologic toxicity were
based on the neutrophil and platelet counts on the day of
administration. The dose of gemcitabine was reduced by 25 or
50%, respectively, if the ANC was 1.25–1.499 10
9 or 1.0–
1.249 10
9l
 1, or if platelets were 75–99.999 10
9 or 50–
74.999 10
9l
 1. The gemcitabine dose was withheld in the case
of ANC o0.999 10
9l
 1 or platelets o50 10
9l
 1; once the
neutrophil count was X1.5 10
9l
 1 and the platelet count
X100 10
9l
 1, subsequent treatment was delivered at 75% of
the previous dose. If non-haematological CTC grade 3 or 4 toxicity
occurred (excluding alopecia, nausea, or vomiting), treatment was
withheld until toxicity returned to, or was better than, grade 1.
Subsequent treatment was 75% of the previous dosage. The
induction period was not allowed to exceed 5 weeks; deferred
weekly cycles were missed rather than extending the induction
treatment period.
Follow-
up Rest Continuous 5FU infusion
Radiotherapy
4 weeks
G-G-G-R
Gemcitabine
induction
(1 cycle)
12 weeks
Gemcitabine
consolidation
(3 cycles)
G = gemcitabine
R = rest
4 weeks 6 weeks
G-G-G-R  G-G-G-R  G-G-G-R
Figure 1 Study design.
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5FU was given by continuous intravenous infusion. A starting dose
of 200mgm
 2day
 1, 7 days a week, was given, beginning on the
first day of radiation therapy and continuing until the completion
of radiation treatment. The infusion was discontinued for at least 7
days in the case of a fall in ECOG performance status by one class
or greater; weight loss 410% over the duration of treatment; or
any of the following grade 3 or 4 symptoms: nausea or vomiting
not controlled by maximal antiemetic therapy; stomatitis; diar-
rhoea; hand-foot syndrome; ANC o1.0 10
9l
 1 or platelet count
o50 10
9l
 1; and febrile neutropaenia. Resumption of 5FU (with
a 25% dose reduction) was not started until toxicity receded to
pgrade 1. Missed weeks of 5FU infusion were not made up, to
avoid prolonging the radiochemotherapy.
Radiotherapy
Patients were immobilised using a reliable set up apparatus, and
required to be supine with arms over head during simulation and
treatment. Planning CT scan thickness needed to be no thicker
than 5mm and not greater than 5mm intervals to minimise the
extent of volume averaging and provide good tumour and normal
tissue imaging. Oral contrast was recommended to be seen in
the duodenal loop and intravenous contrast to assist definition of
the major abdominal arterial structures. The planned target volume
was the gross tumour volume þ1cm and the dose prescription
was 54Gy in 30 daily fractions of 1.8Gy in accordance with
International Commission on Radiation Units (ICRU) 50 princi-
ples (ICRU, 1993). An additional superior inferior margin was
added for respiratory movement. Normal tissue tolerance dose
constraints for kidney, liver, and spinal cord were as defined in
Table 1 (Emami et al, 1991). Volume extension to incorporate ‘at-
risk’ nodal sites or ‘normal pancreas’ was discouraged because
node prophylaxis in this setting has not yet been shown to be
beneficial, the main site of failure continues to be local mass site
and because radiotherapy-induced toxicity increases with treat-
ment volume size. Field arrangement commonly employed four
axially placed fields, although non-coplanar techniques could be
employed too (and were used in 42.5% of patients) (Osborne et al,
2006).
Discontinuation of radiotherapy for at least 7 days was required
for a fall in performance status by one ECOG class or greater below
ECOG 1, or for grade 3 or 4 toxicity of any of the following: nausea
or vomiting was not controlled by maximal antiemetic therapy;
diarrhoea; platelet count o50 10
9l
 1; and weight loss of 410%.
Resumption of radiotherapy was not allowed until the weight loss
or fall in performance status was reversed, or the toxicities had
receded to pgrade 2, regardless of time missed (except for
haematological toxicity, when it could be recommenced when the
platelet count reached X50 10
9l
 1). It was intended that all
radiotherapy be completed within 8 weeks, including treatment
interruptions. Treatment with radiotherapy took priority over 5FU
infusions: if both treatments were ceased, then reinstitution of
radiotherapy occurred before reinstitution of 5FU infusion,
according to the outlined guidelines.
Efficacy criteria
Objective response was assessed by comparison of pre-treatment
and restaging CT scans (not o4 weeks apart). The products of the
two largest dimensions for individual lesions were compared using
the following definitions. Complete response: disappearance of all
known disease with tumour markers within the normal range.
Partial response: X50% decrease in total tumour size with no
appearance of new lesions or progression of any lesion. Stable
disease: o50% decrease in total tumour size up to a 25% increase
in the size of one or more indicator lesions. Progressive disease:
X25% increase in the size of at least one indicator lesion or the
appearance of new lesions. A responder was defined as a patient
with complete or partial response. Prospective studies have
demonstrated the potential value of changes in CA 19-9 level with
treatment (Maisey et al, 2005; Ferrone et al, 2006). An increase of
15% in serum CA 19-9 over the previous level on two consecutive
occasions 3 weeks apart was considered to suggest progression and
mandate additional investigation by CT scan. Confirmation of
response by consecutive CT scans was not required.
Time-to-event analyses using the Kaplan–Meier method were
calculated from the start of therapy and were not adjusted for
second-line therapies. Survival time was calculated to the date of
death and censored on date last known alive. Time to progression
was calculated to the date of progression or death and censored on
date last known alive. Failure of local control was calculated to the
date of progression in the pancreas and censored on the date of
last scan, if the patient died or completed follow-up without
evidence of local progression. Local progression was defined as
X25% increase in the size of a lesion in the pancreas or the
appearance of a new lesion in the pancreas.
Quality assurance for radiotherapy
The participating radiation oncologist was provided with a
planning scan data set and invited to plan a virtual patient. The
planning review was coordinated through the Sir Charles Gairdner
Hospital in accordance with RTOG/EORTC (Radiation Therapy
Oncology Group/European Organisation for Research and Treat-
ment of Cancer) procedures. This was undertaken at each site,
before the first enrolled patient, to ensure consistent protocol
compliance and correct unintentional ambiguities. Major techni-
que violations were identified in two cases: in one case, the whole
pancreas was included in the planning target volume although it
had been the intention of the protocol to include only the gross
tumour plus a margin, and in the second case, an excessive margin
was employed inferiorly in the post-operative scenario (greater
than the margins in other directions). Ambiguities in the protocol
were identified and corrected, and the replans were acceptable. A
central review of the plans of patients selected at random
underwent quality assurance by a subgroup of radiation oncolo-
gists, which is currently in manuscript preparation. Late toxicity
data were prospectively collected for hepatic and renal adverse
events up to 6 months post-therapy, which is approximately 10
months post-radiotherapy, and cause of death was investigated
retrospectively if either major renal or hepatic function was
involved in the cause of death.
Statistical methods
Exact 95% confidence intervals (CI) are reported. Dose intensity
was calculated from the date of first infusion to the last planned
day of the last cycle the patient received drug. Since the planned
Table 1 Tissue dose tolerance TD 5/5 irradiation of one-third and two-
thirds of target volume
Target volume
TD 5/5 irradiation of
one-third of target
volume (Gy)
TD 5/5 for irradiation
of two-thirds of target
volume (Gy)
Stomach 60 55
Small intestine 50 Not established
Kidney 50 30
Liver 50 35
Spinal cord 50 50
Tolerance dose (TD) for various organs for one-third and two-thirds of target
volume at the 5% complication rate 5 years after treatment. Taken from Emami et al
(1991).
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 2week
 1 for 3 weeks and then
1 week off in a 4-week cycle, the planned dose intensity was
750mgm
 2week
 1, which takes into account the planned week off
and then accounts for any additional delays. SAS v8.2 was used.
RESULTS
Baseline characteristics
The baseline characteristics of the 41 patients enrolled in the
locally advanced arm of the study are shown in Table 2. Patient
attrition is described in Figure 2.
Efficacy
At the end of radiotherapy, one patient (2.4%) had a complete
response and four patients (9.8%) a partial response, for an overall
response rate of 12.2% (Table 3). At the end of consolidation
chemotherapy, three patients (7.3%) had a complete response and
two patients (4.9%) had a partial response, for an overall response
rate of 12.2%. Twenty-four patients (58.5%) had stable disease at
the end of radiotherapy and nine patients (22.0%) at the end of
chemotherapy. Four patients did not start consolidation chemo-
therapy because of progressive disease (Figure 2); progression
was reported in liver (one patient), lung (one), and lymph nodes
(two). Five patients did not complete consolidation chemotherapy
because of progressive disease: ascites (one); progression in
pancreas (one), liver (one), both pancreas and liver (one), and
site not reported (one).
Figure 3 shows the Kaplan–Meier curves for time to progression
and survival. Median time to progression was 7.1 months (95% CI:
6.3, 9.2 months) and median survival time was 11.7 months (95%
CI: 9.7, 13.7 months). The 1- and 2-year survival rates were 46.3%
(95% CI: 31.1, 61.6%) and 9.8% (95% CI: 0.7, 18.8%), respectively.
For the 32 patients who progressed and the first site of
progression could be assessed, 10 patients first progressed locally
(i.e., progression or a new lesion in the pancreas), 27 patients first
progressed systemically, and five patients first progressed both
locally and systemically. Five patients with systemic progression
subsequently also had documented local progression. The most
common site of first systemic progression was liver (12 patients)
and then lung (six patients). Twenty patients (48.8%) failed local
control, 20 patients (48.8%) progressed or died without evidence of
failing local control, and one patient (2.4%) did not progress. The
median time to failure of local control was 11.9 months (95% CI:
8.9, 17.9 months). Figure 3 shows the Kaplan–Meier curve for time
to failure of local control.
Safety
Twenty-three patients (56.1%) reported at least one grade 3
toxicity and seven patients (17.1%) at least one grade 4 toxicity
(Table 4). Treatment-related grade 3 and 4 toxicities were reported
by 16 (39.0%) and four (9.8%) patients, respectively. The majority
of these were haematologic, of which three patients reported grade
4 events, and grade 4 febrile neutropaenia was reported by one
Table 2 Baseline patient characteristics
Characteristic N¼41
Sex 15 (36.6%)
M 26 (63.4%)
F
Age (mean7s.d.) 63.9710.8
Age (range) 30–79
ECOG performance status
a
0 17 (41.5%)
1 21 (51.2%)
2 2 (4.9%)
T stage
T1 4 (9.8%)
T2 12 (29.3%)
T3 16 (39.0%)
T4 8 (19.5%)
TX 1 (2.4%)
N stage
N0 25 (61.0%)
N1 10 (24.4%)
NX 6 (14.6%)
ECOG, Eastern Cooperative Oncology Group.
aThe ECOG performance status of
one patient was unknown.
Commenced consolidation 
gemcitabine therapy (n=34)
Therapy not commenced 
(n=6)
• Personal conflict or other
patient decision (n=2)
• Progressive disease (n=4)
Completed consolidation
gemcitabine therapy* (n=23)
Therapy not completed 
(n=11)
• Protocol completed (n=2)
• Personal conflict or other
patient decision (n=1)
• Physician decision (n=1)
• Adverseevent (n=2**)
• Progressive disease (n=5)
Allocated to locally
advanced arm (n=41)
Commenced radiotherapy
(n=40)
Radiotherapy not commenced
(n=1)
• Personal conflict or other
patient decision (n=1)
Commenced induction
gemcitabine therapy (n=41)
Enrolment
Figure 2 Patient disposition. *A patient was considered to have
completed consolidation gemcitabine therapy if he received three
gemcitabine infusions in the third consolidation cycle. **One patient had
abdominal pain, the other leukopaenia.
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spatient. Treatment-related gastrointestinal toxicities occurred in
five patients (12.2%) with no grade 4 episodes. Two patients
experienced grade 4 cholangitis (one during initial chemotherapy
and one during radiation) and two patients had biliary stent
obstruction (one during radiation and one post-radiation). Two
patients had subacute bowel obstruction (one during radiation and
one post-radiation), which resolved with conservative manage-
ment. There were no episodes of treatment-related ischaemic heart
disease or hand-foot syndrome.
Clinical complications of haematological toxicity were rare:
grade 3/4 infection/febrile neutropaenia was reported by three
patients (7.3%). One patient had radiation recall syndrome. Five
patients required a transfusion of packed red blood cells and one
patient a transfusion of platelets.
During radiotherapy and the following rest period, grade 3/4
haematological toxicity was experienced by 5.0% of patients, and
symptomatic gastrointestinal nausea and vomiting by 10.0 and
5.0% of patients, respectively. Subsequent problems with gastric
outlet obstruction were observed in one patient and no patient
required new biliary stenting. Toxicity attributable to late effects of
radiotherapy was not seen to affect liver, bowel, or spinal cord.
One patient experienced renal failure in the follow-up period. This
patient had end-stage metastatic liver disease with normal renal
function 2 weeks prior; the renal failure was therefore considered
secondary to the progressive disease and neither the radiation nor
chemotherapy treatment.
Haematological toxicity occurred mostly during the gemcita-
bine-alone phases, with grade 3/4 neutropaenia in both the
gemcitabine treatment period before (9.8%) and after (26.5%)
radiotherapy, and grade 3/4 thrombocytopaenia in the gemcitabine
treatment period after radiotherapy (8.8%).
Dose delays and reductions
More patients required a delay or reduction in the post-
radiotherapy gemcitabine doses (30 out of 34 patients, 88.2%)
than in pre-radiotherapy gemcitabine (18 out of 41 patients,
43.9%). Approximately, 60% of patients were able to receive three
cycles of gemcitabine post-radiotherapy (25 out of 41 patients). A
dose adjustment in 5FU was required for 20.0% of patients (eight
out of 40 patients) and in radiotherapy for 20.0% (eight out of 40
patients). Sixteen out of 41 patients did not complete the planned
treatment. This was due to progressive disease for nine out of 41
patients (22.0%); the other seven patients (17.1%) did not
complete therapy because of adverse events (two patients),
personal conflict or other patient decision (two patients – two
because of toxicity), and physician’s decision for treatment effects
(one patient).
Dose intensity
The planned dose intensity for gemcitabine (pre- and post-
radiotherapy) was 750mgm
 2week
 1. The mean achieved and
relative dose intensity of gemcitabine was higher in the gemcitabine
treatment period before radiotherapy (656.7mgm
 2week
 1, 87.6%,
respectively) than afterwards (505.5mgm
 2week
 1, 67.4%).
The planned dose intensity of 5FU was 1400mgm
 2week
 1 and
the mean achieved dose intensity was 1409.1mgm
 2week
 1
(100.7%). The planned dose intensity of radiotherapy was
54Gy over 6 weeks and the mean achieved dose intensity was
52.0Gy (96.2%).
DISCUSSION
There are three pertinent findings from our study: (i) protocol-
specific 3D CRT with sandwich gemcitabine chemotherapy has
acceptable acute toxicity; (ii) this regimen was not associated with
Table 3 Summary of response by visit
End RT (N¼41) End CT (N¼41)
Complete response 1 (2.4%) 3 (7.3%)
Partial response 4 (9.8%) 2 (4.9%)
Stable disease 24 (58.5%) 9 (22.0%)
Progressive disease 6 (14.6%) 15 (36.6%)
Unknown 2 (4.9%) 2 (4.9%)
Not done
a 4 (9.8%)
b 10 (24.4%)
c
End CT, end of gemcitabine consolidation chemotherapy; End RT, end of
radiotherapy.
aReasons not done:
bMoved to another hospital (1), hospitalised with
bowel obstruction (1), patient decision (2).
cMoved to another hospital (1), patient
decision (2+1 due to toxicity), patient admitted to hospital (1), deteriorating health
(1), site error (2), scan done too late (1), no reason given (1).
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Figure 3 Time-to-event measures. (A) Time to progression. (B) Survival
time. (C) Time to failure of local control* (FLC). *Failure of local control
was calculated to the date of progression in the pancreas, and was
censored on the date of last scan if the patient died or completed follow-up
without evidence of local progression, even if the patient progressed
systemically.
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points were encouraging with favorable survival and local control
in this population of patients with locally advanced pancreatic
cancer.
Haematological toxicity, nausea, and vomiting were modest
during radiochemotherapy and the rest period afterwards, and the
radiochemotherapy did not appear to significantly compromise
systemic treatment with gemcitabine in the later months of
therapy. For the majority of patients, not completing the planned
therapy was attributable to disease progression or personal
decisions, not to treatment-related effects. While there were more
reductions and delays in gemcitabine in the consolidation period
than in the induction period, and the dose intensity was therefore
lower in the consolidation period, it was not unduly compromised,
and the majority of patients (60%) were able to receive the planned
three cycles of gemcitabine post-radiotherapy. It should be noted
that the rules for dose adjustments were such that if the
gemcitabine dose was reduced on day 8 or 15 of a cycle, then
the dose would not be re-escalated on day 1 of the next cycle,
which may have contributed to the lower dose intensity as the trial
progressed. Significant late toxicity affecting kidney, bowel, liver,
or spinal cord function was not observed – and these concerns
were prospectively assessed – nor were they observed in our
parallel post-operative study of 22 patients (reported elsewhere).
In addition, there was only one case of subsequent gastric outlet
obstruction and no biliary obstruction. Since we are not reporting
later follow-up at this time, we cannot exclude any very late effects
that may yet occur, but this data regarding the safety of our
approach are encouraging.
The median survival time for patients in this study was 11.7
months, which, along with the 1-year survival rate of 46.3%,
compares favourably with other contemporary CRT phase II
studies (Rich et al, 2004; Wilkowski et al, 2005; Willett et al, 2005).
We did not record whether any second-line chemotherapies were
administered, and we cannot exclude a small contribution to our
survival data from such therapy. In contrast to CRT, chemotherapy
alone has appeared to be associated with inferior survival times in
two recent phase III studies that examined both locally advanced
and metastatic populations. Poplin et al (2006a) reported overall
median survival times of 4.96, 6.01, and 6.47 months in patients
receiving standard gemcitabine treatment, fixed dose rate gemci-
tabine and gemcitabine–oxaliplatin, respectively; median survival
in the locally advanced group was 9.1 months (Poplin et al, 2006b).
Cunningham et al (2005) reported median survivals of 6 and 7.4
months in patients receiving gemcitabine and gemcitabine-
capecitabine, respectively; median survival was 9.9 months in the
locally advanced group (J Neoptolemos, personal communication).
A recent small randomised study comparing gemcitabine alone
with additional combined concurrent cisplatin and 5FU with
external beam radiation for locally advanced disease has been
reported in abstract form (Chauffert et al, 2006). An exceptional
median survival of 14.3 months was reported for the gemcitabine-
alone arm. In contrast, the outcome for the combined therapy arm
was a significantly poorer median survival of 8.4 months, which is
Table 4 CTC grade 3 and 4 toxicities
Regardless of causality Possibly related to therapy
CTC Group Grade 3 (N¼41) Grade 4 (N¼41) Grade 3 (N¼41) Grade 4 (N¼41)
Overall 23 (56.1%) 7 (17.1%) 16 (39.0%) 4 (9.8%)
Blood/bone marrow 14 (34.1%) 3 (7.3%) 12 (29.3%) 3 (7.3%)
Haemoglobin 1 (2.4%) 1 (2.4%) 1 (2.4%) 1 (2.4%)
Leukocytes 9 (22.0%) 1 (2.4%) 9 (22.0%) 1 (2.4%)
Neutrophils/granulocytes 10 (24.4%) 2 (4.9%) 8 (19.5%) 2 (4.9%)
Platelets 3 (7.3%) 0 3 (7.3%) 0
Gastrointestinal 13 (31.7%) 2 (4.9%) 5 (12.2%) 0
Anorexia 1 (2.4%) 0 1 (2.4%) 0
Ascites 1 (2.4%) 0 0 0
Constipation 4 (9.8%) 0 1 (2.4%) 0
Dehydration 2 (4.9%) 0 2 (4.9%) 0
Diarrhoea without colostomy 1 (2.4%) 0 0 0
Dyspepsia/heartburn 1 (2.4%) 0 0 0
Gastritis 1 (2.4%) 0 0 0
Nausea 5 (12.2%) 0 3 (7.3%) 0
Vomiting 3 (7.3%) 0 2 (4.9%) 0
Other gastrointestinal 4 (9.8%) 2 (4.9%) 0 0
Hepatic 3 (7.3%) 2 (4.9%) 1 (2.4%) 0
Alkaline phosphatase 4 (9.8%) 0 0 0
Bilirubin 1 (2.4%) 1 (2.4%) 0 0
GGT 1 (2.4%) 0 0 0
AST 2 (4.9%) 1 (2.4%) 1 (2.4%) 0
ALT 1 (2.4%) 1 (2.4%) 0 0
Infection/febrile neutropaenia 2 (4.9%) 1 (2.4%) 0 1 (2.4%)
Metabolic/laboratory 8 (19.5%) 2 (4.9%) 0 0
Hyperglycaemia 8 (19.5%) 2 (4.9%) 0 0
Pain 7 (17.1%) 0 1 (2.4%) 0
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, g-glutamyl transpeptidase. Patients who reported more than one toxicity are counted more than once in
this table. Relatedness should be treated with caution because some study sites interpreted ‘therapy’ to mean only gemcitabine. Other categories (regardless of causality):
cardiovascular (general) (n¼5): hypertension (two patients), thrombosis (2), and other cardiovascular/general (1); constitutional symptoms (n¼2): fatigue (1) and weight loss
(1); endocrine (n¼1): other endocrine (1); haemorrhage (n¼1): melena/gastrointestinal bleeding (1); neurology (n¼2): CNS cerebrovascular ischaemia (1) and mood
alteration-depression (1); pulmonary (n¼3): dyspnea (1) and pulmonary-other (2); renal/genitourinary (n¼1): urinary frequency/urgency (1). All of these were grade 3 toxicities.
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Explanations for this remain speculative in the absence of detailed
descriptions of the radiotherapy technique and quality assurance
measures employed, but the size of the disparity in outcome does
suggest that the choice of regimens and the radiation technique
and schedule are vital to achieve optimal outcomes.
Good local control was observed in the patients on whom
follow-up data was available, with a local failure rate of 48.8% and
median time to failure of local control of 11.9 months. Since local
progression is often characterised by severe, difficult-to-control
neuropathic pain, we see this outcome as an important measure of
efficacy of this approach. Older studies of radiochemotherapy in
patients with locally advanced pancreatic cancer have had local
failure rates of 58, 72, and 78% (Whittington et al, 1984;
Gastrointestinal Tumor Study Group, 1985; Roldan et al, 1988).
More recent studies of radiochemotherapy have tended not to
report duration of local control but rather first site of relapse, with
local relapse being uncommon as the first site in treated patients
(Blackstock et al, 2003), which makes comparison and interpreta-
tion of the potential impact of radiotherapy more difficult.
The baseline characteristics of the cohort indicate that this study
population is typical of patients with locally advanced pancreatic
cancer, and, in particular, sex, age, and performance status were
not more favourable than those reported in other recent studies
(Blackstock et al, 2003; Rich et al, 2004).
The optimum scheduling of chemotherapy and CRT is not clear.
One approach is to focus on inducing downstaging and subsequent
operability (Wilkowski et al, 2006). The impact of inducing
surgery in initially inoperable patients remains experimental. Our
focus has been on optimising outcomes in the absence of any
further surgery. The use of initial chemotherapy allows identifica-
tion of rapidly progressing patients who do not then undergo
prolonged inappropriate therapy, and may also delay the
emergence of systemic disease, enhancing the benefit of local
control (Moureau-Zabotto et al, 2006; Rana et al, 2006; Huguet
et al, 2007). Despite our finding of some impact on the post-
radiotherapy dose intensity and the significant loss of patients due
to disease progression or personal decisions during treatment,
current chemotherapy agents do not have a high enough response
rate for the CRT to be confidently delayed until the completion of a
standard 6-month chemotherapy programme, considering the
significant problems associated with local progression in tumours
that fail to respond to chemotherapy. Delaying radiotherapy until
month 4 has been proposed on the basis of a recent retrospective
outcome analysis (Huguet et al, 2007) and seems to be a pragmatic
compromise until the emerging novel targeted agents can be
shown to have contributed sufficiently to allow reconsideration of
radiotherapy and chemotherapy scheduling.
We believe that we have demonstrated that protocol-specific 3D
radiochemotherapy with initial and subsequent systemic gemcita-
bine is tolerable, feasible, and effective, and offers good local
control for a substantial proportion of patients with locally
advanced disease. This regimen merits further evaluation as a
foundation for adding novel targeted agents. An optimised
combined regimen should then be studied in a randomised trial
against systemic therapy alone in patients with locally advanced
pancreatic cancer.
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